WAYNE, Pa.–(BUSINESS WIRE)–Intact Vascular, Inc., a developer of medical devices for minimally invasive peripheral vascular procedures, today announced that Steve MacKinnon has joined its senior management team as Vice President of Sales, effective immediately. Reporting to the CEO, Mr. MacKinnon will oversee the creation of a U.S. based sales team and will play a central role in planning and executing the company’s projected launch of the Tack Endovascular System® in 2019.
“Steve brings a stellar track record of sales achievement across a broad range of entrepreneurial medical technology companies,” said Bruce Shook, Intact Vascular’s President & CEO. “Steve’s experience with creating and motivating high performance sales teams, coupled with his deep knowledge of the peripheral vascular market, will be tremendous assets to us as we move toward launch of our flagship product next year.”
Prior to joining Intact Vascular, Mr. MacKinnon was the Vice President of US Sales for Neuronetics [NASDAQ: STIM] where he significantly expanded the sales team and product revenue, and helped take the company public. Prior to Neuronetics, Steve served as Vice President of US Sales for Access Closure and was instrumental in its successful merger with Cardinal Health. He also held multiple sales positions with Fox Hollow Technologies prior to its sale to eV3.
“Intact Vascular represents an exciting opportunity to bring high value innovations to peripheral vascular patients,” said Steve MacKinnon. “I look forward to building a world class sales organization at Intact and to a very successful launch of the Tack Endovascular System.”
About Intact Vascular and the Tack Endovascular System
Intact Vascular is a privately held medical device company that develops minimally- invasive peripheral vascular products. The Tack Endovascular System is designed to improve peripheral balloon angioplasty results in the treatment of peripheral arterial disease. Pre-loaded with six self-expanding nitinol devices for above-the-knee (ATK) interventions, the Tack Endovascular System can be deployed to treat multiple dissections using a single catheter and leaving behind >70% less metal than stents1. Additionally, the Tack Endovascular System offers low radial force, designed to promote healing, improve outcomes and preserve future treatment options for PAD and critical limb ischemia (CLI) patients. Visit http://www.intactvascular.com/ for more information.
This press release contains “forward-looking statements” concerning the development of Intact Vascular’s products, the potential benefits and attributes of such products and the company’s expectations regarding its product launch and other prospects. Forward-looking statements are subject to risks, assumptions and uncertainties that could cause actual future events or results to differ materially from such statements. These statements are made as of the date of this press release. Actual results may vary. Intact Vascular undertakes no obligation to update any forward-looking statements for any reason.
1Bosiers M, Scheinert D, Hendricks JMH et al. Results from the Tack Optimized Balloon Angioplasty (TOBA) study demonstrate the benefits of minimal metal implants for dissection repair after angioplasty. J Vasc Surg 2016;64:109-16.
“CAUTION: Investigational device. Limited by Federal (United States) law to investigational use.”
Tack Endovascular System® is a trademark of Intact Vascular, Inc.
The Tack Endovascular System® is CE Mark Authorized under EC Directive 93/42/EEC.
Not available for sale or use in the United States.
Intact Vascular, Inc.
Andrea Dunkle, 1-484-253-1048